{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T04:18:04Z","timestamp":1793765884896,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40744-026-00826-5","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T15:10:07Z","timestamp":1773933007000},"page":"659-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study"],"prefix":"10.1007","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct04497597","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7929-4827","authenticated-orcid":false,"given":"Andrew","family":"\u00d6st\u00f6r","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Feist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prodromos","family":"Sidiropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Avouac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Rebella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaie","family":"Namas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Buttgereit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip G.","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana B.","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin L.","family":"McDearmon-Blondell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Lagunes-Galindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Kadakia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzan","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"key":"826_CR1","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"826_CR2","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003196","volume":"9","author":"MA Messelink","year":"2023","unstructured":"Messelink MA, den Broeder AA, Marinelli FE, et al. What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis. RMD Open. 2023;9:e003196.","journal-title":"RMD Open"},{"key":"826_CR3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318.","journal-title":"Ann Rheum Dis"},{"key":"826_CR4","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1080\/14397595.2020.1782049","volume":"30","author":"Y Tanaka","year":"2020","unstructured":"Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020;30:779\u201387.","journal-title":"Mod Rheumatol"},{"key":"826_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","volume":"18","author":"Y Tanaka","year":"2022","unstructured":"Tanaka Y, Luo Y, O\u2019Shea JJ, Nakayamada S. Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach. Nat Rev Rheumatol. 2022;18:133\u201345.","journal-title":"Nat Rev Rheumatol"},{"key":"826_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755844","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.","journal-title":"Front Immunol"},{"key":"826_CR7","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","volume":"77","author":"MH Buch","year":"2018","unstructured":"Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018;77:966\u20139.","journal-title":"Ann Rheum Dis"},{"key":"826_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000536","volume":"6","author":"C Hua","year":"2020","unstructured":"Hua C, Buttgereit F, Combe B. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020;6:e000536.","journal-title":"RMD Open"},{"key":"826_CR9","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","volume":"3","author":"YY Tan","year":"2022","unstructured":"Tan YY, Papez V, Chang WH, Mueller SH, Denaxas S, Lai AG. Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43\u2008895 trials and 5\u2008685\u2008738 individuals across 989 unique drugs and 286 conditions in England. Lancet Healthy Longev. 2022;3:e674\u2013e689.","journal-title":"Lancet Healthy Longev"},{"key":"826_CR10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/DHPS.S492887","volume":"17","author":"C Gandy","year":"2025","unstructured":"Gandy C, Bazzazzadehgan S, Bruera S, Huang Y. Evaluation of real-world evidence to assess effectiveness outcomes of Janus kinase inhibitors for rheumatoid arthritis: a systematic review of US studies. Drug Healthc Patient Saf. 2025;17:25\u201349.","journal-title":"Drug Healthc Patient Saf"},{"key":"826_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s40744-024-00651-8","volume":"11","author":"L Bessette","year":"2024","unstructured":"Bessette L, Chan J, Chow A, et al. Real-world effectiveness of upadacitinib for treatment of rheumatoid arthritis in Canadian patients: interim results from the prospective observational CLOSE-UP study. Rheumatol Ther. 2024;11:563\u201382.","journal-title":"Rheumatol Ther"},{"key":"826_CR12","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1093\/rheumatology\/keaa858","volume":"60","author":"J Fitton","year":"2021","unstructured":"Fitton J, Melville AR, Emery P, Nam JL, Buch MH. Real-world single centre use of JAK inhibitors across the rheumatoid arthritis pathway. Rheumatology (Oxford). 2021;60:4048\u201354.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"826_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.reuma.2021.08.001","volume":"18","author":"R Gonz\u00e1lez Mazar\u00edo","year":"2022","unstructured":"Gonz\u00e1lez Mazar\u00edo R, Frag\u00edo Gil JJ, Ivorra Cort\u00e9s J, et al. Real-world effectiveness and safety of JAK inhibitors in rheumatoid arthritis: a single-centre study. Reumatol Clin. 2022;18(9):523\u201330.","journal-title":"Reumatol Clin"},{"key":"826_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s41927-018-0031-x","volume":"2","author":"JM Parmentier","year":"2018","unstructured":"Parmentier JM, Voss J, Graff C, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018;2:23.","journal-title":"BMC Rheumatol"},{"key":"826_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002735","volume":"9","author":"GR Burmester","year":"2023","unstructured":"Burmester GR, Cohen SB, Winthrop KL, et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open. 2023;9:e002735.","journal-title":"RMD Open"},{"key":"826_CR16","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","volume":"391","author":"GR Burmester","year":"2018","unstructured":"Burmester GR, Kremer JM, den Van Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391:2503\u201312.","journal-title":"Lancet"},{"key":"826_CR17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB, van Vollenhoven RF, Winthrop KL, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2021;80:304\u201311.","journal-title":"Ann Rheum Dis"},{"key":"826_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.41032","volume":"71","author":"R Fleischmann","year":"2019","unstructured":"Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019;71:1788\u2013800.","journal-title":"Arthritis Rheumatol"},{"key":"826_CR19","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","volume":"391","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513\u201324.","journal-title":"Lancet"},{"key":"826_CR20","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","volume":"393","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Pangan AL, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393:2303\u201311.","journal-title":"Lancet"},{"key":"826_CR21","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/art.41384","volume":"72","author":"R van Vollenhoven","year":"2020","unstructured":"van Vollenhoven R, Takeuchi T, Pangan AL, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72:1607\u201320.","journal-title":"Arthritis Rheumatol"},{"key":"826_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002658","volume":"8","author":"CT Peter","year":"2022","unstructured":"Peter CT, Bruno F, Yves P, et al. Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe. RMD Open. 2022;8:e002658.","journal-title":"RMD Open"},{"key":"826_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40744-024-00639-4","volume":"11","author":"JF Baker","year":"2024","unstructured":"Baker JF, Zueger P, Ali M, et al. Real-world use and effectiveness outcomes in patients with rheumatoid arthritis treated with upadacitinib: an analysis from the CorEvitas registry. Rheumatol Ther. 2024;11:363\u201380.","journal-title":"Rheumatol Ther"},{"key":"826_CR24","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13075-025-03528-5","volume":"27","author":"A \u00d6st\u00f6r","year":"2025","unstructured":"\u00d6st\u00f6r A, Feist E, Sidiropoulos P, et al. Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study. Arthritis Res Ther. 2025;27:84.","journal-title":"Arthritis Res Ther"},{"key":"826_CR25","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1016\/j.ijsu.2014.07.014","volume":"12","author":"JP Vandenbroucke","year":"2014","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg. 2014;12:1500\u201324.","journal-title":"Int J Surg"},{"key":"826_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0194130","volume":"13","author":"K Ebina","year":"2018","unstructured":"Ebina K, Hashimoto M, Yamamoto W, et al. Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis\u2014the ANSWER cohort study. PLoS ONE. 2018;13:e0194130.","journal-title":"PLoS ONE"},{"key":"826_CR27","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s40744-024-00658-1","volume":"11","author":"R Fleischmann","year":"2024","unstructured":"Fleischmann R, Blanco R, Van den Bosch F, et al. Long-term efficacy and safety following switch between upadacitinib and adalimumab in patients with rheumatoid arthritis: 5-year data from SELECT-COMPARE. Rheumatol Ther. 2024;11:599\u2013615.","journal-title":"Rheumatol Ther"},{"key":"826_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2024-004987","volume":"11","author":"Y Miyazaki","year":"2025","unstructured":"Miyazaki Y, Nakayamada S, Tanaka H, et al. Switching to biological DMARDs versus cycling among JAK inhibitors in patients with rheumatoid arthritis and with inadequate response to JAK inhibitors: from FIRST registry. RMD Open. 2025;11:e004987.","journal-title":"RMD Open"},{"key":"826_CR29","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1093\/rheumatology\/kead309","volume":"62","author":"M Boers","year":"2023","unstructured":"Boers M. Viewpoint: glucocorticoids in the treatment of rheumatoid arthritis: points to (re)consider. Rheumatology (Oxford). 2023;62:3534\u20137.","journal-title":"Rheumatology (Oxford)"},{"key":"826_CR30","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","volume":"396","author":"GR Burmester","year":"2020","unstructured":"Burmester GR, Buttgereit F, Bernasconi C, et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. Lancet. 2020;396:267\u201376.","journal-title":"Lancet"},{"key":"826_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-017-2396-3","volume":"19","author":"L Hartman","year":"2018","unstructured":"Hartman L, Rasch LA, Klausch T, et al. Harm, benefit and costs associated with low-dose glucocorticoids added to the treatment strategies for rheumatoid arthritis in elderly patients (GLORIA trial): study protocol for a randomised controlled trial. Trials. 2018;19:67.","journal-title":"Trials"},{"key":"826_CR32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","volume":"75","author":"C Strehl","year":"2016","unstructured":"Strehl C, Bijlsma JW, de Wit M, et al. Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75:952\u20137.","journal-title":"Ann Rheum Dis"},{"key":"826_CR33","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","volume":"16","author":"F Buttgereit","year":"2020","unstructured":"Buttgereit F. Views on glucocorticoid therapy in rheumatology: the age of convergence. Nat Rev Rheumatol. 2020;16:239\u201346.","journal-title":"Nat Rev Rheumatol"},{"key":"826_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003918","volume":"10","author":"R Fleischmann","year":"2024","unstructured":"Fleischmann R, Meerwein S, Charles-Schoeman C, et al. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5\u00a0years from the SELECT-BEYOND study. RMD Open. 2024;10:e003918.","journal-title":"RMD Open"},{"key":"826_CR35","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s40744-023-00557-x","volume":"10","author":"A Kivitz","year":"2023","unstructured":"Kivitz A, Wells AF, Vargas JI, et al. Long-term efficacy and safety of upadacitinib in patients with rheumatoid arthritis: final results from the BALANCE-EXTEND open-label extension study. Rheumatol Ther. 2023;10:901\u201315.","journal-title":"Rheumatol Ther"},{"issue":"Suppl 1","key":"826_CR36","doi-asserted-by":"publisher","first-page":"1398","DOI":"10.1136\/annrheumdis-2023-eular.1326","volume":"82","author":"DC Diederik","year":"2023","unstructured":"Diederik DC, Durez P, Lenaerts J, Westhovens R, Verschueren P. AB0421 real-world effectiveness of upadacitinib in patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82(Suppl 1):1398\u20139.","journal-title":"Ann Rheum Dis"},{"key":"826_CR37","first-page":"726","volume":"42","author":"T Witte","year":"2024","unstructured":"Witte T, Kiltz U, Haas F, et al. The impact of C-reactive protein levels on the effectiveness of upadacitinib in patients with rheumatoid arthritis: a 12-month prospective, non-interventional German study. Clin Exp Rheumatol. 2024;42:726\u201335.","journal-title":"Clin Exp Rheumatol"},{"key":"826_CR38","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s40264-020-01036-w","volume":"44","author":"PG Conaghan","year":"2021","unstructured":"Conaghan PG, Mysler E, Tanaka Y, et al. Upadacitinib in rheumatoid arthritis: a benefit-risk assessment across a phase III program. Drug Saf. 2021;44:515\u201330.","journal-title":"Drug Saf"},{"key":"826_CR39","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1002\/ueg2.12736","volume":"13","author":"A Goldman","year":"2025","unstructured":"Goldman A, Raschi E, Druyan A, et al. Gastrointestinal perforations associated with JAK inhibitors: a disproportionality analysis of the FDA adverse event reporting system. United Eur Gastroenterol J. 2025;13:566\u201375.","journal-title":"United Eur Gastroenterol J"},{"key":"826_CR40","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2023-0145","author":"M Lanzillotta","year":"2023","unstructured":"Lanzillotta M, Boffini N, Barone E, et al. Safety of Janus kinase inhibitors: a real-world multicenter retrospective cohort study. J Rheumatol. 2023. https:\/\/doi.org\/10.3899\/jrheum.2023-0145.","journal-title":"J Rheumatol"},{"key":"826_CR41","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/joim.13681","volume":"294","author":"X Tong","year":"2023","unstructured":"Tong X, Shen CY, Jeon HL, et al. Cardiovascular risk in rheumatoid arthritis patients treated with targeted synthetic and biological disease-modifying antirheumatic drugs: a multi-centre cohort study. J Intern Med. 2023;294:314\u201325.","journal-title":"J Intern Med"},{"key":"826_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003392","volume":"9","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Choy E, McInnes IB, et al. MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD Open. 2023;9:e003392.","journal-title":"RMD Open"},{"key":"826_CR43","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"826_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12010182","volume":"12","author":"B Frade-Sosa","year":"2022","unstructured":"Frade-Sosa B, Ponce A, Ruiz-Esquide V, et al. High sensitivity C-reactive protein in patients with rheumatoid arthritis treated with antibodies against IL-6 or JAK inhibitors: a clinical and ultrasonographic study. Diagnostics (Basel). 2022;12:182.","journal-title":"Diagnostics (Basel)"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00826-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-026-00826-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-026-00826-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:02:30Z","timestamp":1779530550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-026-00826-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1007\/s40744-026-00826-5","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Andrew \u00d6st\u00f6r has served as a consultant and\/or on advisory boards and\/or undertaken clinical trials for AbbVie, GSK, Janssen, Lilly, Novartis, and Pfizer. Eugen Feist has received honoraria and research grants from AbbVie, BMS, Galapagos, Lilly, MSD, Novartis, Pfizer, Roche, and Sobi. Prodromos Sidiropoulos has received honoraria and research grants from AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB through the University of Crete Special Account for Research. J\u00e9r\u00f4me Avouac has received honoraria from AbbVie, AstraZeneca, Biogen, BMS, Fresenius Kabi, Galapagos, Janssen, Lilly, Medac, MSD, Nordic Pharma, Novartis, Pfizer, Roche-Chugai, Sandoz, and Sanofi; and research grants from BMS, Fresenius Kabi, Galapagos, Novartis (Dreamer), and Pfizer (Passerelle). Martin Rebella has received honoraria and\/or support to participate in academic events from AbbVie, Bayer, Pfizer, and Roche. Rajaie Namas has received speaker fees, research grants, and advisory honoraria from AbbVie. Frank Buttgereit has received consultancy fees, honoraria, travel expenses, and grant support from AbbVie, Amgen (Horizon Therapeutics), Gr\u00fcnenthal, Novartis, and Sparrow. Philip G. Conaghan has received speaker fees or consultancies from AbbVie, Formation Bio, Genascence, Gr\u00fcnenthal, GSK, Kolon TissueGene, Levicept, Lilly, Moebius, Novartis, Pacira, Stryker, and Takeda. Ana B. Romero, Erin L. McDearmon-Blondell, Ivan Lagunes-Galindo, Tianming Gao, Aditi Kadakia, and Tim Shaw are AbbVie employees and may own AbbVie stock or options. Suzan Attar has received speaker fees, research grants, and advisory honoraria from AbbVie, Amgen, AstraZeneca, BMS, Gilead, GSK, Hikma, Janssen, Lilly, Novartis, Organon, Pfizer, Roche, Sandoz, Sanofi, and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted according to the International Council on Harmonisation guidelines and the Helsinki Declaration of 1964 and its later amendments. The trial protocol was approved by independent ethics committees and institutional review boards at each study site. Written informed consent was provided by patients ahead of study screening.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}